Acasti Pharma rises on positive data for genetic disorder drug

Alarko Carrier Sanayi ve Ticaret

28/12/2022 16:30

** U.S.-listed shares of Canadian drug developer Acasti
Pharma Inc  ACST.O  up 6.7% at 51 cents 
    ** Co's drug to treat a type of genetic disorder showed
positive preliminary results in a drug action study
    ** The drug, GTX-102, is an oral spray intended to improve
neurological symptoms of ataxia-telangiectasia (A-T) in
pediatric patients- ACST
    ** A-T is a progressive genetic disorder that primarily
affects young children, causing severe disability and impairment
of the immune system, which currently has no FDA-approved
therapies - ACST
    ** Co expects full dataset from the drug action study in H1
2023, plans to begin a late-stage study for the drug in H2 2023
    ** Including session moves, ACST shares are down ~62% YTD 
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))